Travere therapeutics reports fourth quarter and full year 2023 financial results

Received 459 new patient start forms (psfs) for filspari ® (sparsentan) in q4 2023; total of 1,452 psfs received in 2023

TVTX Ratings Summary

TVTX Quant Ranking